Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cabozantinib
- Development stage
- Approved
- Lead developer
- Exelixis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Cabozantinib is a small-molecule tyrosine kinase inhibitor used as an anti-cancer medication. It works by inhibiting multiple receptor tyrosine kinases involved in tumor growth and angiogenesis, including VEGFR-1, -2, and -3; MET (hepatocyte growth factor receptor); AXL; RET; KIT; TRKB; FLT-3; and TIE-2. By blocking these pathways, cabozantinib suppresses metastasis, angiogenesis, and oncogenesis. It is primarily indicated for the treatment of advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC) in patients previously treated with sorafenib, medullary thyroid cancer (MTC), differentiated thyroid cancer refractory to radioactive iodine therapy or after prior VEGFR-targeted therapy, as well as for certain neuroendocrine tumors. The drug was developed by Exelixis.
- Brand names
- CabometyxCometriq
- Other names
- cabozantinib s-malate
02
Targets
AXL (AXL receptor tyrosine kinase)NTRK2 (Tropomyosin-related kinase receptor type B)MET (Mesenchymal-epithelial transition factor receptor)KIT (c-KIT proto-oncogene receptor tyrosine kinase)TEK (Tie2)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)RET (Rearranged during transfection receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on cabozantinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cabozantinib.